SUDA featured in Business Review Australia

11th February 2016, issuu Business Review Australia by Eric Harding.

Having established a broad technology platform for its oromucosal drug OroMist, SUDA Ltd is now constructing a pharmaceutical business based on reformulated products that demonstrate major cost, functional and effectual advantages over the competition to corner demand.

SUDA holds over 70 patents related to OroMist, covering approximately 300 active pharmaceutical ingredients formulated into patented oral sprays. Using this technology SUDA is developing low-risk, innovative products that improve both patient’s health and lifestyle. It’s a two-pronged business strategy: Either SUDA formulates a market-leading drug in the therapeutic category into a spray, taking it through clinical development to a stage at which the SUDA will out-license the spray; or other companies come directly to SUDA with their molecules and ideas to develop them into spray applications.

“We have what we believe is world-leading technology, expertise and know-how to formulate oromucosal sprays,” said SUDA Chief Business Officer Nick Woolf.

With its some office based in Perth, SUDA has other subsidiaries throughout Western Australia and Europe. Its subsidiary business, called West Coast Surgical and Medical Supplies, provides everything from pharmaceuticals to vaccines for a range of customers.

To read the full article, please click here.